Predictive Oncology Inc. Q1 FY2024 earnings call

• Conducted a retrospective multiyear study with UPMC Magee-Womens Hospital on ovarian cancer, resulting in strong predictive models with high accuracy, and an abstract of the study accepted for presentation at ASCO.
• Collaborated with Fujifilm to co-market EndoPrep sample treatment technology and PYROSTAR bacterial endotoxin detection reagent for biopharmaceuticals.
• Made progress with FluGen on a $6.2 million Phase IIb grant-funded project for an intranasal flu vaccine, leveraging formulations expertise for a stable, refrigerated-soluble vaccine.
• Developed a novel protein expression method for G protein-coupled receptors (GPCRs) and other membrane proteins for drug discovery.
• Collaborated with Cvergenx on genomics-based precision radiation therapy and drug discovery, with progress supported by an NIH SBIR Phase 1 grant.

For the first quarter of 2024, Predictive Oncology recorded revenues of $420,000. The company's Eagan operating segment contributed $404,000 in revenues for the quarter ended March 31, 2024, which is approximately 96.19% of the total quarterly revenue (since $404,000 / $420,000 ≈ 0.9619).

Q: A: Q: A: